Design, synthesis, docking and QSAR study of substituted benzimidazole linked oxadiazole as cytotoxic agents, EGFR and erbB2 receptor inhibitors
作者:Md Jawaid Akhtar、Anees Ahmad Siddiqui、Ahsan Ahmed Khan、Zulphikar Ali、Rikeshwer Prasad Dewangan、Santosh Pasha、M. Shahar Yar
DOI:10.1016/j.ejmech.2016.12.014
日期:2017.1
The synthesis of benzimidazole linked oxadiazole derivatives designed as potential EGFR and erbB2 receptor inhibitors with anticancer and apoptotic activity were studied. Compounds 7a specifically inhibit EGFR and erbB2 receptor at 0.081 and 0.098 μM concentration. Some of the compounds showed strong, broad-spectrum antiproliferative activitiy when tested against five human cancer cell lines. Compounds
研究了被设计为潜在的具有抗癌和凋亡活性的EGFR和erbB2受体抑制剂的苯并咪唑连接的恶二唑衍生物的合成。化合物7a在0.081和0.098μM浓度下特异性抑制EGFR和erbB2受体。当针对五种人类癌细胞系进行测试时,某些化合物显示出强大的广谱抗增殖活性。化合物7a和7n对MCF-7癌细胞的毒性比5-氟尿嘧啶要强,IC 50值为5.0和2.55μM,而只有7a导致细胞周期停滞在G 2 / M期,伴随凋亡增加。化合物7a和7n在心肌病研究中显示出肌原纤维的正常结构,而与对照相比,只有化合物7a显示出几乎相等的生化参数(SGOT和SGPT)。分子对接和3D-QSAR研究用于建立酶活性位点内7a和7n与激酶结构域ATP结合位点的相互作用。